Literature DB >> 16607650

Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.

Tsukasa Sotobori1, Takafumi Ueda, Yusuke Oji, Norifumi Naka, Nobuhito Araki, Akira Myoui, Haruo Sugiyama, Hideki Yoshikawa.   

Abstract

BACKGROUND: There have been several recent reports that Wilms tumor gene (WT1) mRNA is overexpressed in many types of neoplasms, and those results suggested that WT1 has oncogenic properties. The objective of the current study was to evaluate the prognostic significance of WT1 mRNA expression in patients with soft tissue sarcoma.
METHODS: Levels of WT1 mRNA expression were examined by quantitative, real-time reverse transcriptase-polymerase chain reaction analysis in frozen tissue samples from 52 patients with soft tissue sarcoma. Various clinicopathologic factors were analyzed along with the disease-specific survival rate for correlations with WT1 mRNA expression levels.
RESULTS: The levels of WT1 mRNA expression in a variety of soft tissue sarcomas were significantly greater compared with the levels in normal soft tissue samples (P = .0212). No significant correlation was observed between the level of WT1 mRNA expression and clinicopathologic factors, including gender, age, primary tumor site, tumor depth, tumor size, histologic grade, and distant metastasis at initial presentation. The disease-specific survival rate for patients with high WT1 mRNA expression levels was found significantly poorer compared with the rate for patients with low WT1 mRNA expression levels (P = .0182). Moreover, multivariate analysis indicated that a high WT1 mRNA expression level was an independent, adverse prognostic factor for disease-specific survival (hazards ratio, 2.6; P = .0488).
CONCLUSIONS: WT1 mRNA expression level can serve as a potent prognostic indicator in soft tissue sarcoma patients. Copyright 2006 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607650     DOI: 10.1002/cncr.21861

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

Authors:  Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

3.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

4.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tsunekazu Kita; Kazunari Maekawa; Kazuyuki Fujii; Kazuya Kudoh; Kenichi Furuya; Seiichi Tamai; Johji Inazawa; Osamu Matsubara
Journal:  Virchows Arch       Date:  2007-06-27       Impact factor: 4.064

6.  Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma.

Authors:  Jaime F Modiano; Matthew Breen; Rachael Thomas; Huixia J Wang; Pei-Chien Tsai; Cordelia F Langford; Susan P Fosmire; Cristan M Jubala; David M Getzy; Gary R Cutter
Journal:  Chromosome Res       Date:  2009-04-01       Impact factor: 5.239

7.  Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.

Authors:  A Coosemans
Journal:  Facts Views Vis Obgyn       Date:  2011

8.  Prognostic significance of WT1 expression in soft tissue sarcoma.

Authors:  Ahrong Kim; Eun Young Park; Kyungbin Kim; Jeong Hee Lee; Dong Hoon Shin; Jee Yeon Kim; Do Youn Park; Chang Hun Lee; Mee Young Sol; Kyung Un Choi; Jeung Il Kim; In Sook Lee
Journal:  World J Surg Oncol       Date:  2014-07-16       Impact factor: 2.754

9.  Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures.

Authors:  Adrien Daigeler; Ludger Klein-Hitpass; Michael Ansgar Chromik; Oliver Müller; Jörg Hauser; Heinz-Herbert Homann; Hans-Ulrich Steinau; Marcus Lehnhardt
Journal:  BMC Cancer       Date:  2008-10-29       Impact factor: 4.430

10.  WT1 regulates angiogenesis in Ewing Sarcoma.

Authors:  Varalakshmi Katuri; Stephanie Gerber; Xiaofei Qiu; Gregory McCarty; Seth D Goldstein; Hans Hammers; Elizabeth Montgomery; Allen R Chen; David M Loeb
Journal:  Oncotarget       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.